FDA expands Dupixent indication, EU application to follow
![Photo: Rodrigo Cid](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11246740.ece/ALTERNATES/schema-16_9/Dopixent,%2520sanofi,%2520regeneron.jpg)
Eczema treatment Dupixent can now be used by an even wider group of patients in the US, as the FDA has approved an application to extend the use of the drug.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Leo Pharma looking for pediatric patients for eczema trial
For subscribers
Analyst predicts slow start for Leo Pharma's Adtralza in UK
For subscribers
Dupixent drives sales advancement in Sanofi's first quarter
For subscribers